Piper Sandler Maintains Overweight on Altimmune, Maintains $25 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Altimmune (NASDAQ:ALT) with a $25 price target.
June 21, 2024 | 5:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Altimmune with a $25 price target, indicating confidence in the company's future performance.
The reaffirmation of an Overweight rating and a $25 price target by a reputable analyst suggests a positive outlook for Altimmune. This could boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100